0001562180-18-000321.txt : 20180116 0001562180-18-000321.hdr.sgml : 20180116 20180116175750 ACCESSION NUMBER: 0001562180-18-000321 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180112 FILED AS OF DATE: 20180116 DATE AS OF CHANGE: 20180116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CARSCADDEN GWEN R. CENTRAL INDEX KEY: 0001590948 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36545 FILM NUMBER: 18529452 MAIL ADDRESS: STREET 1: C/O INTERSECT ENT, INC. STREET 2: 1555 ADAMS DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intersect ENT, Inc. CENTRAL INDEX KEY: 0001271214 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 200280837 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1555 ADAMS DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-641-2100 MAIL ADDRESS: STREET 1: 1555 ADAMS DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: SINEXUS INC DATE OF NAME CHANGE: 20031124 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-01-12 false 0001271214 Intersect ENT, Inc. XENT 0001590948 CARSCADDEN GWEN R. C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025 false true false false Chief People Officer Common Stock 2018-01-12 4 M false 10000.00 12.19 A 13856.00 D Common Stock 2018-01-12 4 S false 10000.00 34.3476 D 3856.00 D Stock Options (Right to buy) 12.19 2018-01-12 4 M false 10000.00 0.00 D 2026-06-27 Common Stock 10000.00 40000.00 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $34.55. inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. The shares subject to the option vest commencing June 27, 2016. 25% of the shares subject to the option vested on June 27, 2017 and 1/48th of the shares subject to the option vests monthly thereafter over three (3) years. David A. Lehman, Attorney-in-Fact for Gwen Carscadden 2018-01-16